Best Electrolyte Supplements Ranked 2026

Electrolyte Supplement Comparison Table — GLP-1 Fit Rankings

Research Context

GLP-1 medications — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Saxenda) — create an electrolyte depletion profile that is fundamentally different from general exercise-induced hydration loss. When food intake drops 30–50% under appetite suppression, dietary sodium, potassium, and magnesium intake collapse with it. The result is a predictable side-effect cluster: fatigue, muscle cramps, brain fog, headaches, and dizziness that are not medication side effects per se — they are electrolyte gaps masquerading as medication intolerance.

Most electrolyte products on the market were designed for athletes with normal caloric intake. They are either inadequate for the GLP-1 sodium depletion gap (low-sodium tablets, Liquid IV's 500 mg) or contain sugar that conflicts with GLP-1 glycemic management goals (DripDrop, standard sports drinks). This ranking specifically scores electrolyte protocols for their fit with the GLP-1 user context — sodium adequacy, sugar burden, GI tolerability, magnesium coverage, and practical daily use adherence.

LMNT ranks first because 1000 mg sodium, zero sugar, and a clean ingredient list match the GLP-1 depletion profile most accurately of any single-product option. The magnesium-electrolyte stack ranks second because it adds multi-pathway side-effect coverage — constipation, cramps, and sleep disruption — beyond basic hydration. Precision Hydration PH 1500 is the standout for active GLP-1 users with significant sweat losses. Lower-ranked options are not necessarily bad; they are simply mismatched to the GLP-1 context.

The market for electrolyte supplementation for GLP-1 users is crowded with simplified claims. This guide focuses on which protocols actually match the sodium, potassium, and magnesium depletion demands of GLP-1 therapy, caloric restriction, and the associated side-effect cluster and organizes the available evidence so readers can compare what was studied, how strong the evidence is, where it may apply, and what important limitations remain.

ProtocolRank uses an editorial evidence-to-decision lens rather than a clinically validated scoring model. Randomized trials, systematic reviews, mechanistic work, observational evidence, practical burden, and known safety constraints can all be relevant, but they do not carry the same weight and they do not automatically transfer from a study population to an individual reader.

Individual response varies with baseline health, sleep, nutrition, medications, training history, age, sex, comorbidities, and the exact formulation or intervention used. A higher editorial position is therefore a starting point for comparison, not a universal recommendation.

Read this page as educational decision support, not medical advice. If an option affects a chronic condition, prescription medication, pregnancy, psychiatric or endocrine history, or another meaningful safety issue, use the evidence here to prepare a better discussion with a qualified clinician rather than to self-prescribe.

If this decision includes peptide, TRT, or performance-clinic variables, cross-check provider quality and care-model differences here: Peaked Labs: TRT Provider Comparisons and Peaked Labs: Peptide Provider Pages.

For peptide-specific protocols, visit peakedlabs.com. For longevity deep-dives, visit alivelongevity.com.

How We Ranked These Protocols

Our editorial methodology for electrolyte supplement ranking for GLP-1 users compares evidence quality, applicability, downside risk, implementation burden, and the relevance of outcomes such as sodium adequacy for GLP-1 depletion context, sugar burden, GI tolerability, magnesium coverage, potassium delivery, cost per effective serving, and daily adherence probability. These dimensions help organize the literature; they are not a validated clinical prediction model.

Randomized controlled trials and systematic reviews generally provide stronger causal evidence than mechanism studies, uncontrolled observations, anecdotes, or surrogate markers. We also look for whether the studied population, formulation, dose, comparator, and outcome match the claim being made.

Practical burden matters because an intervention that is difficult, expensive, or hard to monitor may be less useful even when the biological rationale is plausible. Products were penalized when sodium levels fell below 800 mg per serving — the minimum threshold for meaningful GLP-1 dietary sodium gap replacement. Products with significant sugar content were also penalized given the GLP-1 glycemic management context. Any numeric or ordinal ordering on ProtocolRank should be interpreted as editorial prioritization, not a quantified probability of benefit.

Finally, each option sits inside a broader medical and behavioral context. Sleep, nutrition, training, medications, comorbidities, and clinician-supervised care can change both the expected benefit and the risk. The comparison should narrow the questions worth asking; it should not replace individualized review where that review is appropriate.

We separated three electrolyte contexts within the GLP-1 population: (1) daily preventive maintenance for users with reduced dietary sodium, (2) active exercise days where sweat loss compounds the dietary depletion, and (3) acute dehydration events on high-nausea days when oral rehydration is the priority. The optimal protocol can differ across all three.

Palatability and GI tolerability received extra weight in this ranking because GLP-1 users frequently experience nausea, delayed gastric emptying, and GI sensitivity. An electrolyte protocol that triggers nausea or GI discomfort in an already sensitive user fails regardless of its electrolyte profile. Products with clean ingredient lists and minimal artificial sweeteners scored higher for this reason.

Cost per effective serving was assessed relative to GLP-1 use duration — these medications are typically used for 6–24 months. Electrolyte costs over a sustained period are a real consideration. DIY approaches score well on cost but require setup investment that not all users will execute.

Implementation Playbook

• • Clarify the decision first: define the specific electrolyte supplementation for GLP-1 users outcome you care about and what evidence would meaningfully change your mind.
• • Check whether the evidence matches your situation: population, baseline status, formulation, comparator, duration, and outcome should be close enough to make the result relevant.
• • Separate study protocol from personal instruction. A dose, schedule, or progression used in a paper describes what was studied; it is not automatically appropriate for an individual reader.
• • Review contraindications, medication interactions, pregnancy considerations, laboratory monitoring needs, and other safety constraints before treating an intervention as actionable.
• • Prefer one clearly defined decision at a time so benefits, adverse effects, and confounders are easier to interpret. For medically consequential interventions, make that decision with a qualified clinician.
• • Predefine what would count as useful, ineffective, or concerning and when the decision should be revisited. Avoid extending an intervention simply because it was ranked highly on this site.
• • Step 7: Estimate your dietary sodium intake while on GLP-1 — most users consuming 1000–1400 calories are getting 800–1200 mg sodium from food vs a normal 2300+ mg. The gap is 1000+ mg/day.
• • Step 8: Choose a product with at least 800–1000 mg sodium per serving for daily maintenance; scale up for workout days or high-nausea periods.
• • Step 9: Add magnesium glycinate 200–400 mg before bed if you experience cramps, sleep disruption, or constipation — magnesium addresses 4 GLP-1 side effects simultaneously.
• • Step 10: Separate electrolyte supplement timing from GLP-1 injections by 30–60 minutes if experiencing injection-site nausea that is worsened by supplements taken close together.